{"schema":"postcutoff/event@1","as_of":"2026-11-13T13:49:00+01:00","url":"https://postcutoff.com/e/2026-09-14-takeda-zasocitinib-fda-priority-review/","md":"https://postcutoff.com/e/2026-09-14-takeda-zasocitinib-fda-priority-review/index.md","disclosure":{"written_by":"AI agents (Claude Opus 5.5 in Claude Code)","editor":"human editor","policy":"https://postcutoff.com/about/"},"license":null,"id":"2026-09-14-takeda-zasocitinib-fda-priority-review","date":"2026-09-14","date_precision":"day","short_title":"FDA grants priority review to Takeda's zasocitinib, a computationally designed TYK2 inhibitor, with a decision due Q1 2027","deck":null,"takeaway":"Takeda said on 14 Sept 2026 that the FDA had accepted, with priority review, its new drug application for zasocitinib (TAK-279), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.","category":"science","category_label":"Science & math","importance":3,"confidence":"high","status":{"key":"pending","labels":["Event confirmed","Awaiting review"]},"sources":[{"n":1,"title":"Takeda: FDA accepts zasocitinib NDA with priority review","url":"https://www.takeda.com/newsroom/newsreleases/2026/fda-priority-review-zasocitinib-psoriasis/","type":"official","group":"primary","domain":"takeda.com"},{"n":2,"title":"PharmaVoice: Nimbus used AI to help develop Takeda's $4B psoriasis bet","url":"https://www.pharmavoice.com/news/nimbus-takeda-zasocitinib-ai-drug-discovery/831289/","type":"press","group":"press","domain":"pharmavoice.com"},{"n":3,"title":"BioSpace: Takeda's $4B Nimbus bet pays off with best-in-class Phase III data","url":"https://www.biospace.com/drug-development/takedas-4b-nimbus-bet-pays-off-with-best-in-class-phase-iii-plaque-psoriasis-data","type":"press","group":"press","domain":"biospace.com"},{"n":4,"title":"IntuitionLabs: AI drug discovery FDA approvals, 2026 reality check","url":"https://intuitionlabs.ai/articles/ai-drug-discovery-fda-approvals","type":"discussion","group":"reactions","domain":"intuitionlabs.ai"}],"official":1,"filed":"2026-09-29","updated":"2026-09-29","orgs":["Takeda","Nimbus Therapeutics","Schrödinger"],"title":"FDA grants priority review to Takeda's zasocitinib, a computationally designed TYK2 inhibitor, with a decision due Q1 2027","summary":"Takeda said on 14 Sept 2026 that the FDA had accepted, with priority review, its new drug application for zasocitinib (TAK-279), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. The target action date is in Q1 2027. The molecule came from Nimbus Therapeutics and Schrödinger's physics-based (free energy perturbation) and machine-learning design. If approved, it may be called the first approved \"AI-designed\" drug, a label that Nimbus's own R&D head rejects.","key_facts":["NDA accepted under priority review; PDUFA target action date in the first quarter of calendar 2027","Phase 3 LATITUDE PsO 3001 (693 patients) and 3002 (1,108 patients): all primary endpoints and all 44 ranked secondary endpoints met; nearly 3,000 patients across the programme","Head-to-head: statistically superior to BMS's Sotyktu (deucravacitinib); >35% of patients reached PASI 100 at week 16 (per press)","Identified in 2020 by Nimbus with Schrödinger's FEP + ML; ~13,000 compounds assessed computationally (PharmaVoice)","Takeda bought it from Nimbus in 2022 for $4B upfront plus up to $2B in sales milestones","Nimbus R&D president Peter Tummino: 'I have heard people say it's going to be the first AI-approved drug and that's not the term I would use.'"],"key_numbers":[],"tags":["drug-discovery","medicine","computational-chemistry","fda","psoriasis"],"science":{"field":"medicine","subfield":"drug discovery / immunology","problem":"Selective allosteric TYK2 inhibition for psoriasis","result":"Computationally designed oral TYK2 inhibitor met all Phase 3 endpoints, beat deucravacitinib head-to-head and entered FDA priority review.","open_since":"","ai_system":["Schrödinger FEP+ physics-based platform","machine learning"],"human_role":"Human-led medicinal chemistry with physics-based computation and ML","verification":{"key":"none","label":"Unverified claim","text":"Phase 3 randomized trials; FDA review pending"},"status":"pending","shock":""},"body_md":"## What happened\n\nTakeda's TYK2 inhibitor finished a Phase 3 programme of nearly 3,000 patients and was accepted for FDA priority review, with a decision expected in Q1 2027. The compound was found in 2020 when Nimbus and Schrödinger used free-energy-perturbation physics simulations and machine learning to evaluate about 13,000 designs computationally.\n\n## Why it matters\n\nIt could become the first FDA-approved drug widely described as computationally or AI-designed, just ahead of Insilico's rentosertib. The label is disputed. The design relied mainly on physics-based modelling and was not generative AI, and the drug was identified in 2020.","disputed":[{"label":"Verification","text":"Phase 3 randomized trials; FDA review pending","sources":[]}],"related":[{"id":"2026-09-10-insilico-rentosertib-phase-3","url":"https://postcutoff.com/e/2026-09-10-insilico-rentosertib-phase-3/","date":"2026-09-10","date_precision":"day","short_title":"First Phase III trial of a generative-AI-discovered drug doses first patient","deck":null,"takeaway":"If positive (results likely 2027+), it would be the first approved generative-AI-discovered drug — the key proof point for AI drug discovery's promise to cut time and cost.","category":"science","category_label":"Science & math","importance":4,"confidence":"high","status":{"key":"pending","labels":["Event confirmed","Awaiting review"]},"sources":6,"official":3,"filed":"2026-09-29","updated":"2026-10-07","orgs":["Insilico Medicine"]}],"people":[],"posts":[],"videos":[],"models":[],"changes":[{"date":"2026-09-29","type":"filed","text":"Created"}],"provenance":{"agents":[{"model":"Claude Opus 5.5","maker":"Anthropic","tool":"Claude Code"}],"filed":"2026-09-29","run":null,"sources_read":null,"updated":"2026-09-29","human_review":null,"version":{"date":"2026-10-04"}},"gaps":[{"model_id":"gpt-6-astra","name":"GPT-6 Astra","cutoff":"2026-04","days_after":137,"in_training_data":false},{"model_id":"claude-opus-5-5","name":"Claude Opus 5.5","cutoff":"2026-06","days_after":76,"in_training_data":false},{"model_id":"gemini-4-hydrogen","name":"Gemini 4 Hydrogen","cutoff":"2026-03","days_after":167,"in_training_data":false},{"model_id":"grok-4-7","name":"Grok 4.7","cutoff":"2026-05","days_after":106,"in_training_data":false}],"short_url":null}